However, more research is needed to determine whether there is an overlap between the MDR-TB and HIV epidemics worldwide.
然而，还需要进行更多研究才能确定耐多药结核病和艾滋病在全球的流行是否有重叠。
Today, only some 3% of these estimated cases of MDR-TB are being treated according to WHO standards, while many more MDR-TB patients are mismanaged by various public and private providers.
今天，在耐多药结核估计病例中只有约3%根据世卫组织标准进行治疗，而不同的公立和私立医疗提供者对更多的耐多药结核病人处理不当。
Almost 50% of MDR-TB cases worldwide are estimated to occur in China and India.
估计全世界将近50%的耐多药结核病例发生在中国和印度。
A second way of developing MDR-TB or XDR-TB is when a patient's own TB develops resistance.
形成耐多药结核或广泛耐药结核的第二个途径是患者自身的结核产生耐药性。
All the countries receiving this assistance have met WHO's technical standards for managing MDR-TB and already have treatment programmes in place.
所有接受此项援助的国家均已符合世卫组织的管理耐多药结核技术标准，并已经具备治疗规划。
That means not only saving the people with MDR-TB but also the general population.
这不仅意味着拯救耐多药结核病人，也拯救所有的人。
For countries with a strong private sector, such as the Philippines, the cost of treatment is prohibitive for most patients with MDR-TB.
在具有强大私营部门的国家，如菲律宾，治疗费用对大多数耐多药结核病患者来说过分高昂。
But how many of those cases are MDR-TB?
但这些病例中有多少是耐多药结核病？
MDR-TB is a form of TB that fails to respond to standard first-line drugs.
耐多药结核病是一种对一线标准药物没有反应的结核病形式。
Projections for 2008 are much less than the target of 98 000 that was set in the Global MDR-TB/XDR-TB Response Plan.
2008年预计人数比全球耐多药结核/广泛耐药结核应对计划中规定的98 000人的目标要少得多。
People living with HIV have a higher risk of MDR-TB, with a greatly increased mortality and a greatly reduced survival time.
感染艾滋病毒者罹患耐多药结核病的风险较大，其死亡率大幅上升，存活时间大大减少。
The drugs for the lengthy treatment of MDR-TB can cost more than 100 times that of the drugs to treat common tuberculosis strains.
用于疗耐多药结核病漫长治疗的药品费用比治疗常见结核病菌株的药品可能贵100倍以上。
Q: What concerns you about fighting MDR-TB in the future?
问：你对与耐多药结核病作斗争的前途有什么看法？
Worldwide, of those patients receiving treatment, 60% were reported as cured. However, only an estimated 7% of all MDR-TB patients are diagnosed.
全球范围内，接受治疗的病人当中，有60%报告治愈，但耐多药结核病病人中，只有大约7%得以确诊。
Parts of China had some of the highest rates of MDR-TB in the world.
在中国的某些地区，MDR - TB的发生率已经达到了世界最严重的程度。
MDR-TB takes longer to treat with second-line drugs, which are more expensive and have more side-effects.
用二线药物治疗耐多药结核所需时间更长，更加昂贵，并且产生更多副作用。
In support of the Beijing meeting's aims, planning tools are being developed to help countries scale up their MDR-TB control efforts.
为了支持北京会议的目标，帮助各国扩展耐多药结核病控制的计划工具正在开发中。
These regions join two countries, Estonia and Latvia, which have reversed rising high rates of MDR-TB, ultimately achieving a decline.
这两个地区同爱沙尼亚和拉脱维亚两个国家都扭转了耐多药结核病发病率升高的局面，最终实现了下降。
Wherever second-line drugs to treat MDR-TB are being misused, the possibility of XDR-TB exists.
在治疗耐多药结核的二线药物被滥用的任何地方，存在着广泛耐药结核的可能性。
We also recognize that MDR-TB case Numbers are high, and that we expect more XDR-TB cases.
我们也认识到耐多药结核病例数目甚高，而且我们预计会出现更多的广泛耐药结核病例。
Further tests revealed those who failed treatment had MDR-TB; officials realized they had an epidemic of these cases.
进一步的检测显示，那些治疗失败的病人患的是耐多药结核病，官员意识到了耐多药结核病的流行。
This was 8.5% of the estimated global total of smear-positive cases of MDR-TB.
这仅相当于痰涂阳性耐多药结核病例全球估计总数的8.5%。
Q: When did you start getting involved with MDR-TB?
问：你什么时候开始介入耐多药结核病问题的？
The Philippines has tried to control multidrug-resistant TB (MDR -TB ) for nearly as long as any country in the world.
菲律宾像世界任何国家一样，长期以来设法控制耐多药结核病。
As a result all kinds of poor management of MDR-TB are happening.
因此，出现各种耐多药结核病管理不善的情况。
Some early results have been encouraging: One Almaty hospital, for instance, reported an 80% cure rate of MDR-TB patients in 2008.
初步结果令人鼓舞，如阿拉木图某医院报告，2008年耐多药结核病例治愈率为80%。
Since 2009, the 23 countries most heavily affected by TB drug resistance have nearly doubled their budgets for MDR-TB.
自2009年以来，受到耐药结核病影响最重的23个国家已经将用于耐多药结核病的预算几近翻番。
It is time for countries with rapidly growing economies and a heavy burden of MDR-TB to step up their commitment and financing for their own MDR-TB programmes.
对那些经济增长很快并且面临耐多药结核病沉重负担的国家而言，现在到了加强承诺并为自身的耐多药结核病项目提供资助的时候了。
Previous reports found high levels of mortality among people living with HIV and infected with MDR-TB and XDR-TB.
以前的报告中发现，艾滋病毒携带者同时感染耐多药结核病和广泛耐药结核病的病例中死亡率很高。
Q: Aside from money, what has been the most important factor in running a MDR-TB treatment programme?
问：除了钱外，什么是开展耐多药结核病治疗规划的最重要因素？
应用推荐